Zenith Capital Corp Stock Fundamentals
| ZHCLF Stock | USD 0.11 0.01 10.00% |
Zenith Capital Corp fundamentals help investors to digest information that contributes to Zenith Capital's financial success or failures. It also enables traders to predict the movement of Zenith Pink Sheet. The fundamental analysis module provides a way to measure Zenith Capital's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zenith Capital pink sheet.
Zenith |
Zenith Capital Corp Company Total Debt Analysis
Zenith Capital's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Zenith Capital Total Debt | 3.94 M |
Most of Zenith Capital's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zenith Capital Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Zenith Capital Corp has a Total Debt of 3.94 M. This is 99.86% lower than that of the Healthcare sector and 98.79% lower than that of the Biotechnology industry. The total debt for all United States stocks is 99.93% higher than that of the company.
Zenith Capital Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zenith Capital's current stock value. Our valuation model uses many indicators to compare Zenith Capital value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zenith Capital competition to find correlations between indicators driving Zenith Capital's intrinsic value. More Info.Zenith Capital Corp is rated first in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zenith Capital's earnings, one of the primary drivers of an investment's value.Zenith Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zenith Capital's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Zenith Capital could also be used in its relative valuation, which is a method of valuing Zenith Capital by comparing valuation metrics of similar companies.Zenith Capital is currently under evaluation in total debt category among its peers.
Zenith Fundamentals
| Return On Asset | -1.6 | |||
| Current Valuation | 23.33 M | |||
| EBITDA | (7.31 M) | |||
| Net Income | (7.8 M) | |||
| Cash And Equivalents | 19 K | |||
| Total Debt | 3.94 M | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.10) X | |||
| Cash Flow From Operations | (847 K) | |||
| Earnings Per Share | (0.06) X | |||
| Beta | -187.63 | |||
| Market Capitalization | 10.44 M | |||
| Total Asset | 2.88 M | |||
| Z Score | -5.4 | |||
| Net Asset | 2.88 M |
About Zenith Capital Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zenith Capital Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenith Capital using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenith Capital Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company was incorporated in 2013 and is headquartered in Calgary, Canada. Zenith Cap operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Zenith Pink Sheet
Zenith Capital financial ratios help investors to determine whether Zenith Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenith with respect to the benefits of owning Zenith Capital security.